US pharma giant Merck & Co (NYSE: MRK) yesterday (October 24) provided an overview of the clinical trial program for V503, the company’s investigational 9-valent human papillomavirus (HPV) vaccine, to the Advisory Committee on Immunization Practices in the USA.
Merck said that the pivotal efficacy trial is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V503 to the US Food and Drug Administration during the current year (2013).
The study evaluated the efficacy, immunogenicity and safety of V503 in females aged 16-26 years. Merck plans to present results from this study, as well as other results from the Phase III clinical program for V503, at the EUROGIN (EUropean Research Organization on Genital Infection and Neoplasia) congress in November.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze